Friday, 23 Aug 2019

You are here

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

Overall, there were 117 incident and 37 recurrent psoriatic events reported. The observed  incidence rates for psoriasis:

  • TNFi IR = 3.04/1,000 PY
  • csDMARDs IR = 0.65/1000 PPY (IRs for abatacept, rituximab and tocilizumab did not differ significantly from csDMARDs.)

Risk of incident psoriasis was higher for TNFi, female sex (HR: 1.7) and smoking (HR: 2.1), but decreased with methotrexate (HR: 0.5).  Comedication of TNFi with methotrexate seems to lower the risk of incident psoriasis.

For recurrent psoriasis, IRs for TNFi, abatacept and rituximab were significantly higher than for csDMARDs.

This reported incidence of TNFi induced psoriasis of 3 per 1000 PY is similar to a previously reported large cohort rate of 1 per 1000 PY.  Nevertheless, the overall risk is low in RA without psoriasis and rare in those with a history of psoriasis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).